IFNA1 and systemic lupus erythematosus: IFNα has become an intriguing therapeutic target in SLE [9,10], given the prominent presence of elevated IFNα levels in SLE patients (reviewed in [11]) and the fact that many patients carry mutations in genes regulating type I IFN production or signaling [12].